Bionano Genomics reported Q4 2024 results and outlined a shift in strategy focusing on routine users. Revenue decreased by 24% to $8.2 million due to discontinued clinical services. The company aims to increase profitability and scalability while providing an outlook for 2025.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay